Many patients achieve their weight-loss goals and maintain them on 1.0 mg or 1.7 mg weekly, finding no additional benefit from advancing to 2.4 mg
Extrapolating, 7.5 mg likely produces results in the 16 to 18% range for most individuals who stay at this dose long-term
interaction p = 0.098 (Figure 4)
Kontraindikacije Ko ne sme da koristi ovaj lek Semaglutid se propisuje u terapiji dijabetesa tipa 2, ne sme se primenjivati kod pacijenata sa dijabetesom tipa 1 stanja kod koga telo uopte ne stvara insulin zbog svog efekta na pankreas, kao i kod pacijenata sa visokim rizikom od dijabetesne ketoacidoze (komplikacija dijabetesa sa visokom koncentracijom eera u krvi, oteanim disanjem, konfuzijom, pojaanim oseajem ei, slatkim mirisom daha ili slatkim ili metalnim ukusom u ustima)
This hormone is integrally linked to the operation of the stomach, liver, and pancreas, as well as to the communication between the brain and digestive system
These findings suggest that the effectiveness of oral semaglutide in reducing HbA1c levels was preserved in individuals who took the drug at times other than the morning fast, provided that a pre- and post-dose fasting was respected
